AstraZeneca ($AZN) and Bind Therapeutics have joined forces in the creation of a kinase inhibitor nanotech for treating cancer, part of Bind's Accurin line of drug-delivery platforms. The collaboration gives AstraZeneca exclusive rights to the development and commercialization of the nanomedicine, while Bind will lead manufacturing. Bind stands to gain up to $69 million in upfront and preapproval funds and more than $130 million in regulatory and sales milestone payments, as well as partial royalties. Report